

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Hsing-Pang Hsieh et al. Art Unit : 1617
Serial No. : 10/817,490 Examiner : Yong Soo Chong
Filed : April 2, 2004 Conf. No. : 2330
Title : Treatment Of Hepatitis C Virus Infection With Sesquiterpene Lactones

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT


In response to the restriction requirement dated March 18, 2008, Applicants elect parthenolide (i.e., the first compound recited in claim 8) as the single sesquiterpene lactone species without traverse.

Claims 1, 2, 4-8, and 27 read on the elected species. Currently, claims 1-32 are pending, among which claims 1-27 have been elected for prosecution. As correctly pointed out by the Examiner, pursuant to 37 CFR 1.141, upon allowance of generic claims 1 and 5, Applicants will be entitled to consideration of the claims to additional species which are written in dependent form or otherwise include all the limitations of allowed generic claims 1 and 5.

No fee is believed to be due. Please apply any other charges to Deposit Account No. 50-4189, referencing Attorney Docket No. 70001-021001.

Respectfully submitted,

Date: 4-1-08


Y. Rocky Tsao, Ph.D., J.D.
Attorney for Application Owner
Reg. No. 34,053

Customer No. 69713
Occhiuti Rohlicek & Tsao LLP
10 Fawcett Street
Cambridge, MA 02138
Telephone: (617) 500-2503
Facsimile: (617) 500-2499
31752.doc